Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Non–Small-Cell Lung Cancer with HER2 Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment

Non–Small-Cell Lung Cancer with HER2 Regression with Dual HER2 Inhibition and Anti-VEGF... CASE REPORT Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,* Filip Janku, MD, PhD,* Anne S. Tsao, MD,† Christel C. Bastida, PhD,* David J. Stewart, MD,‡ and Razelle Kurzrock, MD§ dvances in cancer genome sequencing technologies have Sequenom MassARRAY analysis of the primary Aled to the identification of non–small-cell lung cancer tumor performed in a Clinical Laboratory Improvement (NSCLC) subtypes having distinct potentially actionable Amendments–certified laboratory showed a HER2 exon 20 molecular drivers, including mutations in the kinase domain mutation (insertion 774–775 AYVM) with no other mutations of human epidermal growth factor receptor-2 (HER2), which in an additional 52 tested oncogenes. have been reported in approximately 4% of NSCLC cases. In October 2011, after signing informed consent, the Preclinical and clinical studies demonstrated that HER2 muta- patient received therapy on a protocol approved by the M.D. tions in NSCLC are associated with a favorable response to Anderson Institutional Review Board (NCT00543504) with 2,3 HER2 targeted therapies. a combination of lapatinib, trastuzumab, and bevacizumab. Her baseline computed tomography (CT) of chest, abdo- men, and pelvis revealed metastatic lesions in the right lung, CASE STUDY and a magnetic resonance imaging (MRI) of brain showed a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Non–Small-Cell Lung Cancer with HER2 Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment

Journal of Thoracic Oncology , Volume 8 (2) – Feb 1, 2013

Loading next page...
 
/lp/wolters-kluwer-health/non-ndash-small-cell-lung-cancer-with-her2-regression-with-dual-her2-leusg43Mmz

References (6)

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e31827ce38e
pmid
23328556
Publisher site
See Article on Publisher Site

Abstract

CASE REPORT Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,* Filip Janku, MD, PhD,* Anne S. Tsao, MD,† Christel C. Bastida, PhD,* David J. Stewart, MD,‡ and Razelle Kurzrock, MD§ dvances in cancer genome sequencing technologies have Sequenom MassARRAY analysis of the primary Aled to the identification of non–small-cell lung cancer tumor performed in a Clinical Laboratory Improvement (NSCLC) subtypes having distinct potentially actionable Amendments–certified laboratory showed a HER2 exon 20 molecular drivers, including mutations in the kinase domain mutation (insertion 774–775 AYVM) with no other mutations of human epidermal growth factor receptor-2 (HER2), which in an additional 52 tested oncogenes. have been reported in approximately 4% of NSCLC cases. In October 2011, after signing informed consent, the Preclinical and clinical studies demonstrated that HER2 muta- patient received therapy on a protocol approved by the M.D. tions in NSCLC are associated with a favorable response to Anderson Institutional Review Board (NCT00543504) with 2,3 HER2 targeted therapies. a combination of lapatinib, trastuzumab, and bevacizumab. Her baseline computed tomography (CT) of chest, abdo- men, and pelvis revealed metastatic lesions in the right lung, CASE STUDY and a magnetic resonance imaging (MRI) of brain showed a

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Feb 1, 2013

There are no references for this article.